Abstract 467P
Background
To investigate the application effect of evidence-based concept of cluster management model in oncology nutrition case management.
Methods
Experimental observation was conducted on 60 cases of oncology patients, and the study period was from August 2021 to August 2022. In the process of nutritional case management of the patients, 30 cases were included in the observation group to carry out the evidence-based concept of the cluster management mode; the other 30 patients belonged to the control group and received routine nursing guidance. Observe and compare the nutritional status and nursing satisfaction of the two groups of patients.
Results
Before nursing care, the nutritional status (S-Amy (blood amylase), U-Amy (urine amylase), Alb (serum albumin), etc.) of the patients in the two groups was assessed, and no significant difference existed between the observation group and the control group (P > 0.05); after the implementation of different nursing care measures, the nutritional status of the patients in the two groups was compared again and found to be significantly different, and that the nutritional status of the patients in the observation group was significantly better ( P＜0.05). The results of patients' satisfaction with nursing interventions showed that the observation group (96.7%) was significantly higher than the control group (70.0%), with a significant difference (P < 0.05).
Conclusions
In the nutritional case management of oncology patients, the implementation of the evidence-based concept of cluster management mode can significantly improve the nutritional status of patients, help patients to strengthen their physical fitness, which is beneficial to the control of patients' conditions, and the patients' satisfaction with nursing care is high, which is worthy of promotion.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract
184P - Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
Presenter: Yuki Sonoda
Session: Poster Display
Resources:
Abstract
185P - Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
186P - Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial
Presenter: Xiaoting Ma
Session: Poster Display
Resources:
Abstract
187P - Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
Presenter: Yongguang Wei
Session: Poster Display
Resources:
Abstract
188P - Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Margherita Rimini
Session: Poster Display
Resources:
Abstract
189P - Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Shun Yamamoto
Session: Poster Display
Resources:
Abstract
190P - Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
Presenter: Jiaxing He
Session: Poster Display
Resources:
Abstract
191P - Predictive value of CXCR6 expression in gastric cancer survival and immune modulation
Presenter: Song-Hee han
Session: Poster Display
Resources:
Abstract
192P - Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib + chemotherapy: Results from two prospective studies
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract